Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
6,151 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07405151 | A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) | recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 17, 2026 | clinicaltrials |
| NCT07561073 | Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer | recruiting | N/A | 80 | Guangxi Medical UniversityOTHER | 1 | Sep 17, 2026 |
| NCT07566052 | A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | recruiting | Phase 3 | 356 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 17, 2026 | clinicaltrials |
| NCT07572864 | Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC | recruiting | Phase 2 | 9 | West China HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07585760 | CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment(CAREMM-012) | recruiting | Phase 2 | 26 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07622771 | Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial | recruiting | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07623798 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 | recruiting | Phase 3 | 255 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07639450 | N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors(Solid Tumors) | recruiting | Phase 1 / Phase 2 | 114 | Hefei Xinzhu Biological Technology Co., Ltd.INDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT07760454 | A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 68 | UCARsgen Biotech LimitedOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07778316 | Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)(DeLLphi-315) | recruiting | Phase 3 | 400 | AmgenINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT07824479 | Predicting Efficacy of Preoperative Immunotherapy in Advanced Gastric Cancer | recruiting | — | 120 | Ruijin HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07824791 | Prediction of Postoperative Recurrence in Crohn's Disease | recruiting | — | 250 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | recruiting | Phase 2 / Phase 3 | 626 | Mirati Therapeutics Inc.INDUSTRY | 47 | Sep 16, 2026 | clinicaltrials |
| NCT05283993 | A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | recruiting | — | 2,000 | Peking University First HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05457049 | Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD | recruiting | — | 180 | Guangdong Association of Clinical TrialsOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT05798819 | A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | recruiting | Phase 3 | 424 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06233942 | Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 308 | BeOne MedicinesINDUSTRY | 5 | Sep 16, 2026 | clinicaltrials |
| NCT06427941 | A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 630 | BeOne MedicinesINDUSTRY | 9 | Sep 16, 2026 | clinicaltrials |
| NCT06463587 | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | recruiting | Phase 3 | 264 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 25 | Sep 16, 2026 | clinicaltrials |
| NCT06566079 | Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 160 | InSilico Medicine Hong Kong LimitedINDUSTRY | 2 | Sep 16, 2026 | clinicaltrials |
| NCT06824168 | Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission | recruiting | Phase 2 | 130 | Daiichi SankyoINDUSTRY | 5 | Sep 16, 2026 | clinicaltrials |
| NCT06873555 | A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Heronova PharmaceuticalsINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07071090 | A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 32 | Heronova PharmaceuticalsINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07116213 | Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer | recruiting | N/A | 20 | Xiaorong HouOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07215494 | A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis | recruiting | N/A | 50 | Peking University First HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07492680 | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | recruiting | Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 13 | Sep 16, 2026 | clinicaltrials |
| NCT07527884 | The Effect of Radiotherapy After Separation Surgery for Spinal Metastases | recruiting | N/A | 130 | Wei XuOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07584161 | MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer(ARTISAN) | recruiting | N/A | 228 | Xiaorong HouOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07751341 | A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 84 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07763587 | Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen | recruiting | N/A | 216 | First Teaching Hospital of Tianjin University of Traditional Chinese MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07811193 | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum | recruiting | Phase 2 | 140 | Vividion Therapeutics, Inc.INDUSTRY | 22 | Sep 16, 2026 | clinicaltrials |
| NCT07822646 | A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer | recruiting | Phase 3 | 120 | Chinese PLA General HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822776 | Efgartigimod in Anti-NMDA Receptor Encephalitis.(ANSWER) | recruiting | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823049 | Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy | recruiting | Phase 3 | 226 | Evopoint Biosciences Inc.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823855 | SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC(HP-SIB-AHFRT) | recruiting | N/A | 15 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05334823 | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | recruiting | Phase 2 | 100 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05410145 | A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | recruiting | Phase 1 / Phase 2 | 442 | D3 Bio (Wuxi) Co., LtdINDUSTRY | 10 | Sep 15, 2026 | clinicaltrials |
| NCT05554939 | Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06146946 | Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H) | recruiting | N/A | 1,384 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06730373 | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) | recruiting | Phase 2 | 110 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06899126 | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer(DESTINY-Lung06) | recruiting | Phase 3 | 686 | Daiichi SankyoINDUSTRY | 23 | Sep 15, 2026 | clinicaltrials |
| NCT07061535 | Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer(STAR-SCLC) | recruiting | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | recruiting | Phase 3 | 700 | Incyte CorporationINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
| NCT07367516 | Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 105 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07532018 | DXP-106 in Solid Tumor Patients.(DXP-106) | recruiting | Phase 1 | 54 | Singlomics Biopharmaceuticals Zhuhai Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07588594 | Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia | recruiting | N/A | 31 | Peking University People's HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07620041 | Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction | recruiting | Phase 1 | 48 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
Data updated 13 days agoSource updated unknownsource: clinicaltrials